MYGN.OQ
Latest Trade
26.33USDChange
0.53(+2.05%)Volume
59,203Today's Range
-
26.4252 Week Range
-
30.12As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 25.80 |
|---|---|
Open | 25.52 |
Volume | 59,203 |
3M AVG Volume | 15.95 |
Today's High | 26.42 |
Today's Low | 25.52 |
52 Week High | 30.12 |
52 Week Low | 9.24 |
Shares Out (MIL) | 75.21 |
Market Cap (MIL) | 1,866.72 |
Forward P/E | -171.88 |
Dividend (Yield %) | -- |
Myriad Genetics Forms Strategic Partnership With Illumina In Oncology
Myriad Genetics Provides Transformation Update
Myriad Genetics Reports Q1 Loss Per Share Of $0.20
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
Industry
Biotechnology & Drugs
Contact Info
320 S Wakara Way
SALT LAKE CITY, UT
84108-1214
United States
+1.801.5843600
http://www.myriad.comExecutive Leadership
S. Louise Phanstiel
Independent Chairman of the Board
Paul J. Diaz
President, Chief Executive Officer, Director
R. Bryan Riggsbee
Chief Financial Officer, Executive Vice President, Treasurer
Nicole Lambert
President of Myriad Womens Health, Oncology, and International
Mark S. Verratti
President of Myriad Neuroscience and Myriad Autoimmune
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 3.12 |
Price To Book (MRQ) | 2.05 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 24.70 |
LT Debt To Equity (MRQ) | 24.70 |
Return on Investment (TTM) | -15.37 |
Return on Equity (TTM) | -14.11 |
* MYRIAD ANNOUNCES NEW STUDIES VALIDATING THE ABILITY OF MYRIAD’S RISKSCORE® TEST TO MODIFY BREAST CANCER RISK PREDICTION Source text for Eikon: Further company coverage:
* MYRIAD ANNOUNCES PARTNERSHIP WITH OPTRAHEALTH® TO DELIVER “GENE™” A NEW AI BASED INFORMATION TOOL FOR HEREDITARY CANCER PATIENTS
* CAMBER CAPITAL MANAGEMENT LP REPORTS 5.37% PASSIVE STAKE IN MYRIAD GENETICS INC AS OF JUNE 11 - SEC FILING Source text : (https://bit.ly/2Nj9ZQf) Further company coverage:
* MYRIAD ANNOUNCES NEW FAVORABLE COVERAGE POLICIES FOR PROLARIS® FROM THREE NEW COMMERCIAL HEALTH PLANS INCLUDING MAJOR NATIONAL PROVIDER Source text for Eikon: Further company coverage:
* MYRIAD GENETICS ANNOUNCES PUBLICATION OF A PROSPECTIVE CLINICAL STUDY OF THE ENDOPREDICT® TEST IN WOMEN WITH EARLY-STAGE BREAST CANCER Source text for Eikon: Further company coverage:
* MYRIAD GENETICS SAYS ON MAY 27, BOARD APPROVED INCREASE IN SIZE OF BOARD TO NINE MEMBERS FROM EIGHT - SEC FILING Source text for Eikon: [ID: https://bit.ly/3gxhGzq] Further company coverage:
* MYRIAD GENETICS APPOINTS DANIEL K. SPIEGELMAN TO THE BOARD OF DIRECTORS AND ANNOUNCES UPCOMING RETIREMENT OF JOHN T. HENDERSON, M.D. Source text for Eikon: Further company coverage:
* CERECOR AND MYRIAD GENETICS ANNOUNCE THAT LEVELS OF LIGHT, A NOVEL CYTOKINE, WERE HIGHLY CORRELATED WITH DISEASE SEVERITY AND MORTALITY IN COVID-19 ARDS BIOMARKER STUDY
* MYRIAD RECEIVES FDA APPROVAL OF BRACANALYSIS CDX® AS A COMPANION DIAGNOSTIC FOR LYNPARZA® IN HRR-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* MYRIAD GENETICS REPORTS FISCAL THIRD-QUARTER 2020 FINANCIAL RESULTS
* MYRIAD GENETICS ANNOUNCES PUBLICATION OF A META-ANALYSIS DEMONSTRATING THE CLINICAL UTILITY OF THE GENESIGHT® PSYCHOTROPIC TEST IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER Source text for Eikon: Further company coverage:
* MYRIAD WITHDRAWING FINANCIAL GUIDANCE FOR FY2020 DUE TO BUSINESS IMPACT FROM CORONAVIRUS PANDEMIC
* MYRIAD RECEIVES REIMBURSEMENT FOR THE BRACANALYSIS® DIAGNOSTIC SYSTEM IN JAPAN FOR PATIENTS WITH BREAST OR OVARIAN CANCER ASSOCIATED WITH HBOC Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* MYRIAD GENETICS - SEEKS JAPANESE REGULATORY APPROVAL FOR ITS BRACANALYSIS DIAGNOSTIC SYSTEM IN PEOPLE WITH ADVANCED PANCREATIC AND PROSTATE CANCER Source text for Eikon: Further company coverage:
* MYRIAD GENETICS INC - R. BRYAN RIGGSBEE, CHIEF FINANCIAL OFFICER APPOINTED INTERIM PRESIDENT AND CEO
* MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2020 FINANCIAL RESULTS
* MYRIAD GENETICS INC - R. BRYAN RIGGSBEE, CFO , HAS BEEN APPOINTED INTERIM PRESIDENT & CEO EFFECTIVE IMMEDIATELY & TO CONTINUE TO SERVE AS CFO
* MYRIAD GENETICS REPORTS FISCAL THIRD-QUARTER 2018 FINANCIAL RESULTS
Myriad Genetics Inc - Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca :
* MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2018 FINANCIAL RESULTS
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.